A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 394 participants.
Also called NCT04936035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 394 participants
- Sponsor
- Registry
-
NCT04936035 -
2021-001248-82
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Puerto Rico, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04936035. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-07 (actual); primary completion 2023-04-04 (actual). Results posted on 2024-12-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
- Acronym
- KARDIA-1
- Condition
- Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- ALN-AGT01
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct04936035- Content hash
c785dc36c6981a3de13202f647cd094754d9d6627209803308a5672625b37d51